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1  | INTRODUC TION
Horses are already recognised as models for several human diseases, 
including metabolic syndrome, asthma, musculoskeletal diseases, 
melanoma and autoimmune uveitis.1-6 More than 100 equine hered-
itable conditions may serve as models for human disorders, including 
inflammation, muscular or fertility disorders, osteoarthritis and even 
depression.7-10 The horse has the potential to represent an appropriate 
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Abstract
The mononuclear phagocyte system (MPS) is a family of cells of related function 
that includes bone marrow progenitors, blood monocytes and resident tissue mac-
rophages. Macrophages are effector cells in both innate and acquired immunity. They 
are a major resident cell population in every organ and their numbers increase in 
response to proinflammatory stimuli. Their function is highly regulated by a wide 
range of agonists, including lymphokines, cytokines and products of microorganisms. 
Macrophage biology has been studied most extensively in mice, yet direct compari-
sons of rodent and human macrophages have revealed many functional differences. 
In this review, we provide an overview of the equine MPS, describing the variation 
in the function and phenotype of macrophages depending on their location and 
the similarities and differences between the rodent, human and equine immune re-
sponse. We discuss the use of the horse as a large animal model in which to study 
macrophage biology and pathological processes shared with humans. Finally, follow-
ing the recent update to the horse genome, facilitating further comparative analysis 
of regulated gene expression between the species, we highlight the importance of 
future transcriptomic macrophage studies in the horse, the findings of which may 
also be applicable to human as well as veterinary research.
K E Y W O R D S
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large animal model in which to study basic macrophage biology and 
pathological processes shared with humans, with the advantage that 
insights can be applied in both veterinary and human medicine.
Monocytes and macrophages provide the first line of defence 
against pathogens and play a crucial role in both health and dis-
ease.11 Macrophage biology has been studied most extensively in 
mice, with the data derived from such studies having undoubtedly 
helped to unravel basic physiological mechanisms in health and dis-
ease processes. However, direct comparison of mouse and human 
macrophages has revealed many functional differences.12,13 In con-
trast, important similarities have already been described between 
horse and human macrophages.14-22 In this review, we provide an 
overview of equine macrophage biology and highlight the impor-
tance of future macrophage studies in the horse, the findings of 
which may also be applicable to man.
2  | AN OVERVIE W OF MACROPHAGE 
BIOLOGY AND THE MONONUCLE AR 
PHAGOCY TE SYSTEM IN HUMANS AND 
RODENTS
Macrophages (from Greek ‘μακρόν’ meaning big and ‘φαγείν’ mean-
ing to eat) are large leucocytes that comprise 10%-15% of all cells in 
most organs of all animal species.23-25 They were originally identified 
in the 19th century by Metchnikoff, who distinguished them from 
related microphages, now known more commonly as granulocytes 
or polymorphonuclear leucocytes. Subsequently, van Furth and 
Cohen and others recognised the functional relationship between 
bone marrow progenitors, circulating blood monocytes and resident 
tissue macrophages and proposed the concept of a mononuclear 
phagocyte system (MPS).26,27 The shared functions of cells of the 
MPS include antigen presentation, phagocytosis, cytokine produc-
tion, microbicidal activity, tissue repair and the general regulation of 
tissue homeostasis (Figure 1).
Over the past 5 years there have been numerous studies on the 
development of the MPS in the mouse. Macrophage-like cells first 
appear in the yolk sac without an evident monocyte-like intermedi-
ate, and thence are produced in the fetal liver (reviewed in 28,29). 
Furthermore, lineage-trace studies suggest that many tissue mac-
rophage populations (the notable exception being the large macro-
phage population of the intestinal mucosa) are derived from fetal 
progenitors and maintained in the steady state without substantial 
input from blood monocytes.30-35 Τhe tissue itself plays an import-
ant role in controlling the balance between the persistence of the 
resident macrophage population and the recruitment of circulating 
monocytes at various stages of its maturation.31 Humans with muta-
tions in the IRF8 transcription factor lack blood monocytes, yet have 
tissue macrophages.36 Although these results are often portrayed 
as a contradiction to the MPS concept, the original definition of the 
MPS clearly did recognise the ability of resident macrophages to 
self-replicate.29 Many studies in multiple organ systems have shown 
that blood monocytes can, and do, occupy the vacant territories 
of resident macrophages when these cells are depleted (reviewed 
in 28,29,31,37). It is important to recognise that the lineage-trace 
models that favour the persistence of fetal-derived macrophages 
are open to interpretation.29,37 Furthermore, the recent concepts 
of MPS ontogeny and homeostasis are derived mainly from a single 
inbred mouse strain (C57Bl6) under specified pathogen-free labora-
tory conditions. It is not yet clear that the conclusions derived from 
these studies can be applied even to other mouse strains let alone 
other species, including the horse.29,37,38
Although all tissue macrophages share many surface and 
intracellular markers and a characteristic ramified or stellate 
morphology, they also adapt their function and gene expres-
sion to perform specific functions. For example, hepatic and 
splenic macrophages, which have direct contact with the blood, 
are adapted for erythrophagocytosis and recycling of iron, 
whereas a population of bone marrow macrophages is adapted 
to support erythropoiesis in erythroblastic islands.39 Embryonic 
macrophages have a common gene expression profile, with tis-
sue-specific macrophage adaptation arising mainly in the early 
postnatal period, in parallel with cessation of the major prolif-
erative phase and appearance of organ-specific functions.40,41 
Adaptation is driven in part by expression of specific transcrip-
tional regulators.40 For example, two recent studies described 
in detail the adoption of liver macrophage (Kupffer cell)-spe-
cific gene expression profiles by monocytes recruited following 
Kupffer cell depletion, thus emphasising the roles of transcrip-
tion factors Id3 and Nr1h3.42,43 Macrophages may even adapt to 
multiple specific niches within tissues. For example, Chakarov 
et al. noted that subpopulations of macrophages expressing the 
surface marker Lyve1 are associated specifically with capillar-
ies in the lung and several other tissues.44 Figure 2 summarises 
some of the specific subpopulations that have been described 
in mouse tissues. Recent studies of tissue-specific macrophage 
populations are reviewed in Hume et al.29
Whether or not these resident macrophage populations are 
replenished by monocytes in the steady state, monocytes are re-
cruited to tissues in response to inflammatory stimuli. The gene 
F I G U R E  1   Summary of macrophage functions
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expression profiles of inflammatory monocytes/macrophages differ 
depending upon the nature of the inflammatory stimulus and change 
with time as the stimulus is removed and normal homeostasis is 
restored. Based upon a parallel with the Th1/Th2 dichotomy in T 
cells, there is a prevalent view that macrophage ‘activation’ can be 
divided into M1 or classical (mediated by the Th1 lymphokine, INFG) 
or M2 or alternative (mediated by the Th2 lymphokines, IL-4/IL-13). 
This dichotomy is not supported by transcriptomic analysis, which 
also reveals that few markers of M1/M2 divergence are conserved 
from mouse to human.11,45,46 Recent reviews support a much wider 
spectrum of activation states and also the concept of innate immune 
memory, wherein macrophages retain an epigenetic imprint of previ-
ous exposure to a stimulus such as microorganisms.47
The development and maintenance of the MPS depends upon 
macrophage colony-stimulating factor 1 receptor (CSF1R) and its 
two ligands, macrophage colony-stimulating factor 1 (CSF1, also 
known as M-CSF) and interleukin 34 (IL-34). Mutations of the Csf1r 
in mice, rats and humans are associated with global deficiencies of 
tissue macrophage populations and multi-system developmental ab-
normalities, including severe postnatal growth retardation (reviewed 
in 48). Many of these deficiencies manifest in mice and rats with 
Csf1 mutations, whereas IL-34 appears to be involved specifically 
in the development of macrophages of the brain (microglia) and skin 
(Langerhans cells).49 The requirement for Csf1r for survival of res-
ident macrophages is retained in adults and blocking CSF1R leads 
to progressive depletion of most macrophage populations.50,51 
Conversely, treatment of mice, rats or pigs with recombinant CSF1 
leads to a monocytosis as well as proliferative expansion of resident 
macrophage populations.52-55 These findings, combined with the 
fact that macrophages of the liver and spleen are the main site of 
clearance of CSF1, led to the concept of homeostatic control of the 
entire MPS via the availability of CSF1.37 The exception to this con-
cept is the lung, where another growth factor, granulocyte-macro-
phage colony-stimulating factor 2 (CSF2, also known as GM-CSF), is 
uniquely required for both development and resident macrophage 
homeostasis.56
In this review, we will describe the most studied components of 
the MPS of the horse (Figure 3) and highlight the effect of the mi-
croenvironment on macrophage function and phenotype. Finally, we 
will discuss the potential value of the horse in providing a greater 
understanding of macrophage biology in humans.
F I G U R E  2   Main types of cells comprising the mononuclear 
phagocyte system in adult mammals
F I G U R E  3   Monocyte and macrophage populations in the horse. 
This figure illustrates key monocyte and macrophage populations 
based on studies in the horse. Macrophages in horses have been 
identified by a combination of cell surface markers, including CD14 
and CD163, although studies and reagents are limited in number. 
Macrophages in different tissues express different levels of cell 
surface proteins highlighting the diversity in resident macrophage 
populations. Bone marrow-derived macrophages, which are 
cultured from haematopoietic progenitor cells collected from 
bone marrow, express CD14. Monocytes isolated from peripheral 
blood mononuclear cells (PBMC) using a density gradient express 
CD14, CCL2 and CCL3, whereas monocyte-derived dendritic 
cells cultured in CSF2 and IL-4 express only low levels of CD14 
and CD86 compared to monocytes, but express the dendritic cell 
markers FLT3 and CD206. Other markers used to characterise 
equine dendritic cells include CD172a MHC class II, CD44, CD163, 
CD204 and Bla36 (not shown in figure). Intestinal and peritoneal 
macrophages all express CD163. It is not known if intestinal 
macrophages express CD14 in the horse, although peritoneal 
macrophages do not. Alveolar macrophages express CD14, CD163, 
TLR2, TLR3, TLR4 and TLR9, while pulmonary intravascular 
macrophages have high expression of TLR4 and TLR9. Equine 
pulmonary interstitial macrophages have been shown to express 
TLR9 by immuno-electron microscopy
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3  | THE MONONUCLE AR PHAGOCY TE 
SYSTEM OF THE HORSE
3.1 | Bone marrow-derived macrophage 
differentiation and activation in the horse
Bone marrow-derived macrophages (BMDMs) are primary mac-
rophage cells generated in cell culture. They are derived from progeni-
tor cells and in the presence of the macrophage lineage-specific growth 
factor CSF1 they differentiate and proliferate into macrophages.57 In 
mice, macrophages are routinely generated in vitro from bone mar-
row progenitors for subsequent functional studies.58,59 This approach 
has recently been extended to large animal species expedited by the 
capacity to freeze cells for future culture following recovery.21,60-62 
We have recently published a comparative analysis of RNA-seq data of 
horse BMDM and their response to lipopolysaccharide (LPS) with sim-
ilar data for ruminants (sheep, goat, cow and water buffalo), pig, mouse 
and rat (in press). The analysis reveals conservation of the underlying 
transcription factor repertoire, basal macrophage-specific gene ex-
pression and LPS-inducible cytokines. However, all of the large ani-
mals are clearly distinguished from rodents, and horse macrophages 
have a small set of species-specific macrophage-expressed transcripts 
that will be the subject of future studies.
Similar to other groups,63-65 we have also differentiated equine 
monocytes to macrophages in the presence of horse serum which, 
among other stimuli, contains CSF1 (A.E. Karagianni, 2014, unpub-
lished data). Bone marrow colony assays have been described using 
horse marrow and used to study the transforming actions of equine 
infectious anaemia virus.66 Furthermore, a macrophage cell line (e-
CAS cells) has been derived from equine bone marrow cells67 and 
subsequently shown to have phagocytic capabilities and responsive-
ness to CSF2 and LPS. However, potential problems associated with 
cell lines include contamination by other cells or microorganisms,68 
which can result in molecular and cellular changes in the cell line.69 
These problems have very recently been highlighted by Evans et al,70 
who sequenced the e-CAS cell line and found the cells to likely be of 
mouse rather than horse origin. Finally, equine bone marrow-derived 
mononuclear cells have also been used in cell therapy methodolo-
gies in horses affected with equine asthma, whereby intratracheal 
administration ameliorates the inflammatory response in the lungs, 
resulting in beneficial effects on clinical signs.71 Similar observations 
have already been reported in mice.72
3.2 | Monocyte differentiation and activation 
in the horse
Based mainly on murine literature, during postnatal life, monocytes 
can replace resident macrophages in all major organs and acquire 
their gene expression profile.29 They share the expression of several 
surface markers with macrophages and together with dendritic cells 
(DCs), act as antigen-presenting cells and play a vital role during in-
fection.29 Several studies in multiple organs have found that blood 
monocytes can occupy the vacant territories of tissue macrophages 
when these populations are depleted (reviewed in 28,29,31,37). In 
the horse, similar to other well-studied species, blood is more eas-
ily sampled than bone marrow. Consequently, several studies have 
been conducted on equine monocytes isolated from peripheral 
blood mononuclear cells (PBMC), focusing on their ability to produce 
proinflammatory cytokines, such as TNF and IL-1, under various 
conditions, including LPS stimulation.73-79 Raabe et al64 also demon-
strated the transforming actions of equine infectious anaemia virus 
on equine blood monocytes. Others have shown that equine periph-
eral blood monocytes and monocyte-derived macrophages express 
CXCL10, a Th1 marker, in response to IFN-γ stimulation.80,81 The in-
duction of equine CXCL10 by IFN-γ is also in agreement with human 
and murine studies.82,83
Compared to alveolar macrophages (AMs), equine PBMC ap-
pear more sensitive to low concentrations of LPS, a finding which 
may reflect desensitisation of AMs by chronic low-level stimula-
tion with inhaled proinflammatory agents.84 In humans and mice, 
the macrophage response to LPS can be mediated via two differ-
ent pathways; a myeloid differentiation primary response gene 88 
(MyD88)-dependent pathway, which induces an inflammatory re-
sponse, and/or a MyD88-independent pathway (also known as the 
TIR-domain-containing adapter-inducing interferon-β [TRIF] path-
way), which stimulates the induction of type I interferon (IFN) and 
IFN-inducible genes.85,86 These pathways appear to be conserved 
in horses (Figure 4). In equine macrophages/monocytes, the induc-
tion of genes encoding TNF, IL1B and IL6 was linked to activation of 
the MyD88 pathway, whereas IFNA, C-X-C motif chemokine ligand 
10 (CXCL10) and RANTES (also known as CCL5) were related to the 
TRIF-dependent signalling pathway.87 Even high concentrations of 
LPS failed to significantly activate TRIF-dependent gene expression 
of IFN, CXCL10, RANTES or TNF receptor-associated factor 1 (TRAF1) 
in equine monocytes, suggesting that in contrast to other studied 
mammalian-derived cells, the response of equine monocytes to LPS 
mainly occurs via the MyD88 pathway.87 Furthermore, Ahn et al88 
studied the response of equine PBMC to well-known inflammasome 
activators in other species (including human and mouse), whereby 
equine PBMC were shown to secrete IL-1B, a well-known indica-
tion of inflammasome activation. Based on comparative studies, the 
authors indicated that equine inflammasome activation is similar to 
that in humans, mice and pigs.
As demonstrated in other mammalian-derived cells, TLR2 ligands 
induce a mild inflammatory response in equine PBMC; this is in com-
parison to the much greater response to TLR4 agonists.9,89 Recent 
transcriptomic studies have reported that LPS induces differential 
microRNA expression in equine PBMC in a manner comparable to 
humans, thus facilitating interspecies comparative study of the role 
of microRNAs in the inflammatory cascade during endotoxaemia 
and sepsis.90 Equine monocytes are also responsive to TLR3 stim-
ulation with double-stranded RNA (polyinosinic polycytidylic acid 
[Poly IC]),91 which is dependent upon the TRIF adaptor. In contrast, 
horse monocytes do not express TLR5, thus explaining their lack 
of response to flagellin.92 However, they do express the scavenger 
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receptor CD163,93 as do equine alveolar and peritoneal macro-
phages (PMs).20 Moreover, equine monocytes isolated from PBMC 
using a density gradient express CD14, CD16, CCL2 and CCL3.16,94 
Unlike humans and horses, mice do not have duplicated CD16 gene, 
while CD14+CD16+ have also been detected in humans and horses 
but not in mice.16
The MPS includes antigen-presenting DCs. The term DC is 
loosely applied to any cell that can present antigen to naïve T cells, 
including bone marrow or monocyte-derived cells cultivated in CSF2. 
However, there has been increasing recognition that these ‘DCs’ are 
distinct from those generated in response to FMS-like tyrosine ki-
nase 3 ligand (FLT3L), a cytokine essential for their development; 
are derived from a committed DC progenitor95 and may be better 
considered as an alternative state of macrophage differentiation.37
Monocyte-derived equine DCs96 have also been generated in 
various studies by cultivation in CSF2 and found to express differ-
ent cell markers including FLT3, CD86, CD204, CD206, CD163 and 
low levels of CD14.97-100 Moreover, horse microarrays were used to 
investigate the gene profile of equine immature and mature DC sub-
sets, confirming the existence of two clearly distinct populations.97 
In contrast, comparisons between lung and blood-derived DC of the 
horse showed no morphological differences.101 However, blood-de-
rived DCs expressed higher levels of CD86 and CD172α than those 
in the lung, while both expressed MHC class II and CD44 and, to 
a lower level, the scavenger receptors CD163, CD204 and the B 
lymphocyte antigen Bla36.101 Furthermore, lung DC demonstrated 
higher phagocytic activity compared to their blood-derived counter-
parts.101 Interestingly, others have also reported remarkable age-de-
pendent phenotypic and functional differences between blood 
monocyte-derived DCs from foals and adult horses.102 Following 
bacterial exposure, DCs generated from foals exhibited lower an-
tigen presentation capabilities and produced lower quantities of 
proinflammatory cytokines. In summary, these results highlight the 
influence of both cell origin and ageing on both phenotypic and func-
tional characteristics.
3.3 | The role of the equine resident macrophages in 
intestinal disease
3.3.1 | Resident intestinal macrophages
The gastrointestinal tract (GIT), although internal, has the largest 
surface area in contact with the external environment of all the body 
organs and thus receives a vast and constant antigenic challenge. It is 
therefore not surprising, based on data derived from humans and ro-
dents, that the GIT represents the largest reservoir of mononuclear 
phagocytes in the body.103 They are located throughout all the tis-
sue layers of the intestine and are broadly categorised into two phe-
notypically distinct groups: mucosal or lamina propria macrophages 
(LpM) and muscularis macrophages (MM).
Lamina propria macrophages are found in the mucosa of the 
GIT, predominantly in the lamina propria,104 and in both mice and 
humans express CD64, MHC class II, CD206 and CD163. In con-
trast to human LpM, mouse LpM also express CD11b, CD11c and 
CX3CR1.105 Given their close proximity to the intestinal lumen and 
the potential for constant antigenic challenge, it is not surprising 
that, unlike other tissue macrophages, LpM appear to be in a state of 
‘hyporesponsiveness’.106 In humans, this has been attributed to the 
absence of expression of the LPS receptors CD14107 and TLR4,108 
the downregulation of TLR2,108 their inability to produce proinflam-
matory cytokines, such as TNFα, and the production of the anti-in-
flammatory cytokine, interleukin-10 (IL-10).109,110 In contrast, MM, 
which are located in the serosa, myenteric plexus and muscle layers 
of the mouse and human GIT,111,112 do express CD14113 and TLR4114 
and may participate in endotoxin-mediated responses within the 
muscularis. MM in mice and humans also express CD163, MHC class 
II, CD206 and CD64 with two different subtypes proposed, depend-
ing on the state of activation.105,115
Both LpM and MM survival is dependent upon signalling from 
the CSF1R.51,116 Depletion of LpM using an anti-CSF1R antibody re-
sulted in a disruption to the differentiation and proliferation of intes-
tinal epithelial cells,117 while depletion of MM resulted in disruption 
F I G U R E  4   TLR 2, 3 and 4 signal transduction pathways of 
the horse. Recognition of lipoprotein ligand by TLR2 triggers the 
MyD88-dependant signalling pathway (red arrow). Following 
stimulation with LPS, lipopolysaccharide binding protein (LBP) is 
recruited to transfer LPS via the Lipid A component to CD14 on the 
surface of macrophages/monocytes. This process is followed by the 
formation of a complex with TLR4 and MD2, activation of NFKB 
signalling pathway and cytokine production. In humans and mice, 
the recognition of the LPS ligand results in a conformational change 
in the TLR4 receptor triggering a myeloid differentiation primary 
response gene 88 (MyD88)-dependent pathway and/or a MyD88-
independent pathway (also known as the TIR-domain-containing 
adapter-inducing interferonβ (TRIF) pathway). Equine monocytes 
fail to strongly activate the TRIF pathway in response to LPS (black 
dashed arrow); instead, they respond mainly via the MyD88-
dependent pathway (yellow arrow), resulting in the induction of the 
proinflammatory cytokines TNF, IL1B, IL6 and the anti-inflammatory 
cytokine IL10. In contrast, TLR3 signalling occurs via the TRIF 
pathway (blue arrow), inducing high expression of IFNB, CXCL10 
and RANTES
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of peristalsis in mice, thus demonstrating a role of MM in intestinal 
motility.116 Studies in mice have shown that MM have a slower turn-
over rate than LpM;112 although both are derived from both yolk sac 
and monocytes,35 LpM in both mice and humans are continuously 
replaced by blood monocytes.118,119 This monocyte infiltrate is also 
important for tissue repair following inflammation, as demonstrated 
in a mouse model of post-operative ileus (POI).120 CD163 has been 
used to identify mucosal and MM in the horse.121-123 MAC387 has 
also been used to identify mucosal macrophages in horses, although 
this nonspecific macrophage marker is also expressed by granulo-
cytes.124,125 CD163+ macrophages are present in all tissue layers of 
the equine small and large intestine, although the distribution of cells 
is not uniform.123 Different cell densities were observed between 
the different tissue layers (lamina propria, submucosa and muscu-
laris externa). Within the submucosa, there was also a higher density 
of CD163+ cells in the large intestine compared to the small intes-
tine. This increase in density of CD163+ cells could be a consequence 
of the higher increase of bacterial content in the intestinal lumen of 
the large intestine compared to the small intestine.
The role of macrophages in humans and rodents has been clearly 
demonstrated in various intestinal pathologies of the GIT, particularly 
in POI and inflammatory bowel disease (IBD).126-129 Despite both 
these conditions occurring in horses (reviewed in 130 and 131), the 
study of macrophage responses in equine intestinal disease is very 
limited. The identification of macrophages in the cellular infiltrate of 
equine IBD cases is a criteria considered in the sub-categorisation 
of disease; macrophage infiltrate is associated with granulomatous 
enteritis and multisystemic eosinophilic epitheliotropic disease but 
not with lymphocytic-plasmacytic enterocolitis or idiopathic eo-
sinophilic enterocolitis.130 However, these cellular-based disease 
sub-categories are generally based on haematoxylin and eosin 
staining; to date, no studies have used specific markers to study 
different macrophage subpopulations in horses, as has been done 
in mice129 and humans.128 Although Little et al132 used calprotectin 
as a macrophage marker in an equine model of intestinal manipula-
tion; calprotectin is also expressed in neutrophils and monocytes. 
This study did demonstrate an intestinal manipulation-induced local 
inflammatory response in horses, similar to that of rodents and 
humans which ultimately leads to smooth muscle dysfunction and 
POI.126,127 Intestinal ischaemia and reperfusion in horses results in 
an increased phagocytic activity of CD163+ macrophages without a 
change in numbers, suggesting their potential role in the resolution 
of inflammation121 and supporting CD163 as a macrophage marker 
for pro-repair (or M2) macrophages.133 Thus, CD163 expression in 
resident equine intestinal macrophages123 suggests that the normal 
equine GIT is populated with intestinal macrophages associated with 
an anti-inflammatory phenotype. By contrast, human studies have 
demonstrated a contribution of CD163+ cells to the amplification 
of inflammation in the mucosa in IBD patients.134 Furthermore, the 
proinflammatory mediators, IFN-γ, LPS and TNF, are found to sup-
press the expression of CD163 in human monocytes,135 suggesting 
that CD163 may be regulated by both pro- and anti-inflammatory 
mediators. Given the relative sparsity of studies of macrophage 
populations of the intestine of the horse, it is difficult to draw con-
clusions. There remains a need for further study of immune cell pop-
ulations in the equine GIT and development of additional markers.
3.3.2 | Equine peritoneal macrophages
The peritoneal cavity is another major source of macrophages for 
functional studies in rodents, in many cases following injection of an 
irritant or infectious agent.136 This anatomical compartment has also 
been a commonly used source of macrophages in mice. In this spe-
cies, resident PMs have a unique expression profile dependent upon 
the transcription factor, Gata6.137,138 PMs have also been isolated 
and studied in humans139 and pigs.140 The function of peritoneal-
derived macrophages is likely to be influenced by their close proxim-
ity to the GIT, potentially acting as a defence against any breach of 
the integrity of the intestinal wall which may result in exposure to 
intestinal luminal-derived microflora and various bacterial-derived 
products.141 One of the genes that is highly expressed in resident 
macrophages in mice and humans is Vsig, encoding the surface recep-
tor CrIG. In humans, CrIG-positive macrophages in the peritoneum 
are associated with disease severity and susceptibility to infection in 
patients with liver disease and ascites.142,143
Peritonitis is a significant clinical issue in horses, most commonly 
associated with surgery for indications such as colic.144 LPS stim-
ulation of equine PMs induced the significant production of pros-
tanoids and proinflammatory cytokines,145-147 but did not produce 
nitric oxide (NO).17 This LPS-induced response could be suppressed 
by high concentrations of dexamethasone, as well as by IL-10.17,148 
Interestingly, LPS-induced TNF production from PMs harvested 
from healthy horses was significantly increased compared to PMs 
derived from horses with acute gastrointestinal disease, leading to 
the suggestion that PMs harvested from the latter group may have 
developed early endotoxin tolerance in response to disease-asso-
ciated endotoxaemia.149 However, in this study there was marked 
horse-to-horse variation, and the authors relied on measuring TNF 
bioactivity rather than protein expression.
We have also reported on the failure of equine PMs, immedi-
ately isolated from euthanised horses, to produce TNF in response 
to LPS, Poly IC and heat-killed S. typhimurium stimulation. This cell 
population expressed both CD163 and TLR4, but not CD14.20 Other 
studies also reported that the LPS responsiveness of equine PMs 
was neither dose- nor time-dependent, as assessed by a TNF bioas-
say.17,146,148 Previous studies on the LPS responsiveness of equine 
PMs used cells harvested from live horses, whereby peritoneal fluid 
is collected from the most dependent abdominal site of standing sub-
jects, likely containing a PM population which has gravitated at this 
location.17,146,148 In contrast, the collection procedure we adopted to 
harvest PMs from euthanased horses involved high volume lavage 
of the entire abdominal cavity, potentially resulting in the isolation 
of a PM population more representative of the entire abdominal 
cavity including those loosely adherent to the peritoneum. Finally, 
site-dependent differences in the differential gene expression of 
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AMs and PMs derived from euthanased horses also supported the 
influence of the tissue microenvironment on macrophage function 
and phenotype.22
3.4 | Pulmonary macrophages: key players in the 
immune defence of the equine lung
At least three types of macrophages have been identified so far in 
the lungs: the AMs, the interstitial macrophages (IMs) and the pulmo-
nary intravascular macrophages (PIMs). PIMs are absent in healthy 
humans and mice, but are present in horse, sheep and other spe-
cies.150,151 Published studies, mainly in mice, have differed in their 
conclusions with respect to the existence of significant functional 
differences between these populations of lung macrophages.152-156 
As bronchoalveolar lavage (BAL) is a practical and commonly used 
method of obtaining resident airway cells, there are several pub-
lished transcriptome analyses of BAL-derived AMs in different spe-
cies, including large animals such as pigs,157 sheep61 and horses.22 
They are clearly distinct from other tissue macrophages, expressing 
many lectin-like receptors apparently adapted to recognise, inter-
nalise and eliminate inhaled microorganisms. The resident AMs arise 
during embryogenesis and self-renew throughout life without major 
replacement from circulating monocytes.32 However, yolk sac-de-
rived monocytes/macrophages, blood monocytes or bone marrow 
transplanted into Csf2r−/− mice can re-establish the missing popula-
tion and successfully differentiate to AMs.158
In comparison, IMs are located in the bronchial and not the alve-
olar interstitium and more closely resemble blood monocytes and are 
therefore clearly distinct from AMs.151,156 Moreover, recent transcrip-
tomic studies also described three newly identified IM subsets in the 
murine lung at steady state.156 Despite the functional, morphological 
and transcriptional differences between these two cell types, both are 
essential for lung homeostasis and immune responses.151,154
Although most equine-based studies have focused on the func-
tion of AMs and their response to various stimuli, more recently, 
Lee et al101 studied the different subpopulations of myeloid cells 
in equine lung tissue. This latter study highlighted the differences 
and similarities in the function and phenotype of lung and blood my-
eloid cells. Both interstitial and AMs are thought to contribute to 
airway inflammation. For example, in severe equine asthma (SEA), 
a common environmental respiratory disease in adult horses, cer-
tain hay dust-derived components, including endotoxin and fungal 
spores, activate macrophages, resulting in the induction of chemo-
kines, such as IL-8 and macrophage inflammatory protein 2 (MIP-2) 
or CXCL2159,160 and the subsequent recruitment of neutrophils to 
the airway.161-167 This neutrophil accumulation in turn leads to free 
radical and protease-mediated tissue damage, a process also seen in 
human studies.168-170
Respiratory infections or airway inflammation are very common 
in horses; even subtle inflammatory responses within the airway can 
have important consequences, particularly in equine athletes.171,172 
Racehorses commonly develop airway inflammation during training, 
with prevalence rates as high as 70%-80%.173,174 Lung macrophages 
may be the primary or secondary site of infection and/or the source 
of inflammatory cytokines in several important infectious and non-
infectious equine diseases, including equine arteritis virus, equine 
influenza, equine herpesvirus 2 and both mild to moderate equine 
asthma (MMEA) and SEA.65,159,175-177
Moreover, a few studies have assessed the influence of training 
on immune cell function specifically within the lung, a key consid-
eration in light of the recently reported disassociation between the 
response of equine monocytes and AMs to training.178 Both an exer-
cise-associated reduction in equine AM phagocytic capacity179 and 
a training-associated derangement in the responsiveness of equine 
AMs to various TLR ligands have been reported, theoretically re-
flecting an increased susceptibility to opportunistic infection.178 In 
agreement, we recently demonstrated a training-associated alter-
ation in equine AM basal gene expression, which was also consistent 
with a degree of immunosuppression at the level of the airways.180
Bacteria, such as Streptococcus zooepidemicus, Streptococcus 
pneumoniae and Pasteurella/Actinobacillus species, constitute 
opportunistic pathogens in the equine airway, triggering the 
respiratory immune system and inducing inflammation.181,182 
Exposure to other factors, such as Aspergillus fumigatus and hay 
dust, have also been shown to induce an inflammatory response 
via the activation of AMs.183 LPS, a significant component of or-
ganic dust derived from equine bedding and forage, is considered 
a major factor in the induction of airway inflammation in stabled 
horses.183 Werners and Bryant184 reviewed the limited literature 
relating to structure-function relationships among pattern recog-
nition receptors (PRRs) in horses. Early studies found that equine 
AMs produced large amounts of TNF in response to LPS, but were 
significantly less responsive to bacterial LPS than blood mono-
cytes, requiring 100-fold higher concentration to induce proco-
agulant activity.84 Subsequently, Suri et al185 demonstrated that 
TLR4, but not TLR2, is constitutively expressed in healthy horse 
lungs, with TLR2 being induced by LPS in IMs, a finding also re-
ported in murine, human and porcine macrophages.12,186,187 It is 
likely that increased expression of TLR2 is a consequence of TLR4 
signalling in response to LPS, as shown in mice.188 More recently, 
Waldschmidt et al189 reported that, in contrast to equine skeletal 
muscle tissue cells, equine AMs responded efficiently to TLR2, 3 
and 4 ligands. Furthermore, AMs show high expression of the spe-
cific macrophage markers CD14, CD163, TLR2, TLR3 and TLR4, 
have high phagocytic activity and are activated when stimulated 
with various proinflammatory ligands, thus supporting the impor-
tance of the local microenvironment in the activation status of the 
macrophage.20 TLR9, the receptor that recognises unmethylated 
CpG oligodeoxynucleotide DNA,190 is expressed by equine lung 
cells, including interstitial and AMs, with its expression also being 
upregulated by LPS stimulation.191 Similarly, TLR9 is expressed in 
mouse and human lung macrophages; its expression is also being 
enhanced by LPS.192,193
Whereas normal mouse and human lungs have no PIMs, they are 
detected in the capillary endothelium of horses and other species, 
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such as cattle, pig and sheep, and are recognised as a member of 
the MPS.150,160,194,195 Equine PIMs are considered proinflammatory 
cells that play a critical role in equine lung inflammation, since they 
secrete the proinflammatory cytokines, TNF and IL-1B, and phago-
cytose in response to LPS.196 Depletion of equine PIMs by gadolin-
ium chloride resulted in a decreased severity of LPS-induced lung 
inflammation, reflected in a reduced mean pulmonary arterial pres-
sure and lower IL-1B production in PIM-depleted horses compared 
to controls.196 Furthermore, depletion of PIMs in horses affected 
with SEA resulted in a reduction in both clinical symptoms and lung 
inflammation, characterised by a reduced airway neutrophil count 
and a decrease in IL8 and TLR4 mRNA detected in airway-derived 
cells.197 Equine PIMs have been shown to express TLR4 and TLR9, 
and the expression of TLR2, TLR4 and TLR9 in horse lungs was aug-
mented after LPS treatment.185,191 As PIMs are capable of directly 
responding to inflammatory stimuli within both the airway and in-
travascular compartments, they have a unique role in pulmonary 
immunity, perhaps explaining the recognised susceptibility of the 
horse to endotoxaemia.150 Recently, Harrison et al198 reported an 
increased expression of inflammatory molecules, such as TLR4 and 
TLR9, in mononuclear cells in the lungs of septic foals, potentially 
including PIMs (see Figure 3). This group also reported an increase 
in PIMs from foals that died from sepsis, compared to healthy ani-
mals. Although PIMs are not observed in healthy humans, there is 
evidence of their existence in patients with liver disorders.199-202
4  | THE HORSE A S AN ANIMAL MODEL 
FOR HUMAN DISE A SE RESE ARCH
The mouse is the most widely used animal model for studying 
human disease; however, many differences exist between mice and 
humans.13,203-205 As well as the obvious environmental, anatomical, 
pathophysiological and genetic differences, there are many distinc-
tions in their innate immune responses,12,60,203,204,206 with specific 
relevance to mechanistic differences in common inflammatory con-
ditions, such as trauma, burns or endotoxaemia.13 One such differ-
ence between rodents, humans and horses is their sensitivity to LPS, 
with horses and humans both having a relatively greater sensitivity 
than rodents. The estimated lethal dose of LPS in humans is thought 
to be approximately 0.015-0.03 µg/kg207,208 and 50-200 µg/kg in 
the horse.209 In contrast, the LD50 dose in the mouse is 25.6 mg/
kg.210 Despite the clear differences between horses and humans 
with respect to LPS lethal dose, the fact that this difference is sig-
nificantly less than that between mice and humans suggests that the 
horse may be a comparably more appropriate model to study the re-
sponse to LPS in humans. Horses, like other daylight-active animals 
including humans and pigs, have evolved differently to nocturnal 
animals, such as the mouse. Comparisons between the LPS-induced 
gene expression of equine AMs and BMDMs and that of other spe-
cies have revealed significant similarities with human-derived cells 
and significant differences with murine-derived cells, further sup-
porting the potential suitability of the horse as a model of human 
innate immune responses, both systemically and at the level of the 
lung.20-22 Further investigation of these interspecies similarities is 
clearly warranted; for example, via Cap analysis gene expression or 
RNA-seq. Findings derived from such studies could provide further 
insights into the inherently high level of sensitivity to LPS shared by 
both humans and horses. In turn, this may facilitate the identifica-
tion of novel therapeutic targets for both endotoxaemia and sepsis 
in man, an objective which has been met with limited success via the 
use of rodent models. Similar studies have already been performed 
in other large animal models such as pig and sheep.60,61,211
The Lipid A component of LPS is detected by macrophages via 
the PRR, TLR4, and the co-receptors, CD14 and MD2. The Lipid 
A component of LPS varies in structure between different bac-
terial species. This results in a variation in TLR4-mediated host 
responses.212 These variations in Lipid A structure also result in in-
terspecies differences in ligand recognition. For example, the Lipid 
A from Salmonella enterica serovar Typhimurium is an agonist in all 
species studied. The Lipid IVa structure of Escherichia coli is a par-
tial agonist in horses,213 whereas in humans it is a full antagonist,214 
and a full agonist in mice.215 Similarly, differences in Rhodobacter 
sphaeroides Lipid A recognition also exist between mice, humans and 
the horse.216 Likewise, there are species differences in the recogni-
tion of lipopeptides by the PRRs TLR1 and TLR2.217 TLR2 recognises 
bacterial antigens by forming heterodimers with TLR1 or TLR6 in 
both humans and horses. Although the response of TLR2/1 to the 
synthetic bacterial lipopeptides Pam2CSK4 and Pam3CSK4 is dif-
ferent between horse and human, the recognition of Pam2CSK4 by 
TLR2/6 is analogous between these species.217 Walsh et al213 found 
sequence differences in the MD2-TLR4 complex between species. A 
consequence of these differences was variation in the local charge 
distribution on the MD2-TLR4 complex. This suggests that the abil-
ity of Lipid IVa recognition, and subsequent signal transduction, is 
governed by electrostatic forces, with only partial contact between 
the ligand and MD2-TLR4 complex potentially resulting in reduced 
signalling; such a phenomenon may explain the interspecies differ-
ences in response to Lipid IVa.
Nitric oxide, a product of inducible NO synthase, is a major ef-
fector secreted by activated macrophages in rodents; however, it is 
not produced by human or porcine macrophages.21,60,203 Instead, 
LPS-stimulated human and porcine macrophages metabolise tryp-
tophan through the induction of indoleamine dioxygenase (encoded 
by the IDO gene), kynurenine hydroxylase and kynureninase; in con-
trast, mouse macrophages do not use this pathway.60,218,219 Among 
ruminant species, cattle and water buffalo macrophages produce 
detectable NO and inducible NOS2 mRNA, whereas sheep and goat 
macrophages do not.21 This difference was associated with inser-
tions of an LPS-responsive mobile genetic element in the NOS2 
promoter. While Hammond et al220 reported an increase in NOS2 
mRNA in equine AMs after LPS challenge, with the consequent pro-
posal that the NOS2 enzyme might be a therapeutic target; others 
have failed to replicate this finding.221 Equine alveolar and BMDMs 
did not produce detectable NO, nor express NOS2 mRNA or other 
transcripts required for NO production in response to LPS.20,21 This 
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difference between species is associated with promoter evolution. 
There is clear conservation between the human and horse promot-
ers and the poor alignment of the promoter sequences between 
mouse/horse and mouse/human.20,21 Finally, the comparative anal-
ysis of LPS-induced global gene expression of equine AMs with that 
of other species revealed significant similarities with human-derived 
AMs and significant differences with murine-derived cells, support-
ing the potential suitability of the horse as a model of human lung 
inflammation and endotoxaemia.22
The full clinical significance of these differences is not yet fully 
understood; nonetheless, there is clear evidence of interspecies 
variation in innate immunity. Such differences likely influence the 
relative magnitude of the response of horses to LPS, or indeed 
other pathogen-associated and damage-associated molecular 
patterns. Such interspecies differences have resulted in an ever 
increasing demand for novel animal models (eg pig) in the study 
of various human diseases; namely those which more closely re-
semble human pathophysiology, compared with rodents.187,222,223 
In comparison to rodent models, the use of horses as appropriate 
models for the generation of data applicable to human disease re-
search has clear practical, financial (eg feeding, housing and han-
dling) and genetic limitations. However, there are also significant 
advantages of this approach, as proposed by other authors (sum-
marised in Table 1).2,6,10,224,225
Horses are animals with a high monetary value, and which require 
considerable investment from their owners. This is particularly true 
of equine athletes, whereby morbidity of any kind can result in sub-
stantial financial losses. Horses can suffer from an extensive range 
of infectious and inflammatory diseases, some of which are zoonotic, 
others of which share certain clinical and pathological features with 
equivalent human diseases.226-228 For example, POI is a life-threat-
ening complication in horses,131 but is also a significant clinical issue 
TA B L E  1   Comparisons of horse and mouse models for human diseases
Comments Horse Mouse References
General Body, organ, litter size, longevity Closer to human Less similar 93,245
Breeding costs High Low
Sample population, possible 
experiment repetition
Small Big
Availability of immunological tools/
reagents
Limited High
Genetic Genetic diversity High Low 244,251-253
Homology of protein coded genes 
with human
High Low
Human CD16 is replicated Replicated Not replicated
Syntenies with human High Low
Chromosome conservation with 
human
High Low
Genome annotation Poor High
Macrophage Biology CD14+CD16+ monocytes observed 
in humans
Detected Not detected 14-21
NO production in macrophages in 
response to LPS
Similar Less similar
Response to LPS Similar Less Similar 21,22
Diseases >100 hereditary conditions served 
as models for humans
Yes No 1-3,6,7,9,10,74,265-
268
Musculoskeletal 
disorders-osteoarthritis
Common Less common
Human endotoxaemia-sepsis 
pathophysiology
Similar Less similar
Asthma—chronic obstructive 
pulmonary disease pathophysiology
Similar Less similar
Human exercise pathophysiology/
immunology
Similar Less similar
Human infectious diseases Similar Less similar
Human mental and behavioural 
disorders
Similar Less similar
Human metabolic diseases Similar Less similar
Therapeutic strategies Translational application to humans Possible Less possible 6,10,269,270
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in humans. Furthermore, racehorses resemble elite human athletes 
and can suffer similar consequences in terms of repetitive injuries 
and exercise-associated pathology, including arthritis and respira-
tory tract infections. For example, racehorses commonly develop 
neutrophilic airway inflammation (MMEA) during the early phase of 
training.173,174 MMEA significantly impairs athletic performance171 
and has a clear association with entry into training, with a reduction 
in prevalence as training progresses.229,230 Although entry into race 
training may result in increased airborne exposures to infectious and 
noninfectious agents, it is also associated with a significant increase 
in exercise intensity and frequency. The well-recognised associa-
tion between high intensity exercise and symptoms of respiratory 
infection among human athletes has fuelled interest in the impact of 
training on immune function. This phenomenon, known as the ‘open 
window’ theory, reflects a temporal association between intense ex-
ercise and increased susceptibility to opportunistic infection.231,232 
Despite localisation of inflammation to the airways in MMEA,171 few 
studies have assessed the influence of training on immune cell func-
tion specifically at this anatomical site, a key consideration in light of 
the previously mentioned disassociation between the response of 
equine monocytes and AMs to training.178,180
As with many domesticated animals, selective breeding of horses 
has produced an array of breeds with specific traits relating to ap-
pearance (size and colour), temperament and performance (speed, 
strength and gait), resulting in more than 450 different breeds 
with a significant degree of diversity.233,234 Given the nature of 
line-breeding, each breed is likely to harbour breed-associated nat-
urally occurring mutations, which may be associated with enhanced 
susceptibility or resistance to various diseases, many of which share 
characteristic features with specific diseases in humans. In light 
of these potential commonalities, the use of technologies, such as 
next-generation sequencing and genome-wide association studies, 
could facilitate the detection of quantitative trait loci or even spe-
cific genes involved in disease susceptibility. Furthermore, there are 
potential benefits of using genetic studies in horses in order to study 
human diseases. Indeed, more than 130 equine hereditary traits re-
lating to specific equine diseases and disorders have already been 
suggested as valuable models for the study of human equivalents,235 
(OMIA: https://omia.org/home/).
Genetic predisposition to equine respiratory tract diseases has 
recently been reviewed by Gerber et al.236 In this respect, SEA (syn. 
recurrent airway obstruction), a common equine respiratory dis-
order and a recognised model for human asthma, dominates the 
field of interest with certain chromosomal regions having already 
been linked to SEA and several candidate interleukin genes having 
been detected in these regions.237,238 IL4RA, a polymorphic gene 
involved in the Th2 response, has been recognised as a major candi-
date gene related to both human asthma and SEA susceptibility.239 
Nonetheless, a few contradictory results have already been pub-
lished regarding the role of this gene, suggesting loci heterogeneity 
for such conditions and highlighting the dual effect of genetic back-
ground and environmental factors on their development.237,239,240 
These findings reflect the complex pathogenesis and pathogenetic 
heterogeneity of both the human and equine forms of asthma, that 
in many cases has been characterised by a mixed as well as a polar-
ised T helper cell immune response.241-243
Many genes involved in immune function have a greater level 
of similarity between human and horse, than between human and 
mouse.244-246 Milenkovic et al244 identified 113 conserved segments 
between the equine and human genome. For example, IL2 showed 
72% identity with human and both IL23 and IL17 showed greater nu-
cleotide sequence identity with human (89% and 84% respectively) 
than mouse (77% and 75% respectively).246 Similarly, equine IFN-γ-
induced chemokine CXCL9 has 86% homology with human, but only 
74% with the mouse.247 Moreover, it is evidenced that CD14 as well 
as TLRs 2-5 and 9 are highly conserved between human and horse 
(Figure 5). With specific relevance to macrophages, equine CSF1R 
is similar to human CSF1R, containing 21 exons which code a 968 
amino acid protein within a 30 kb region.248-250 Steinbach et al245 
reported on the capacity for equine CSF2 to induce proliferation 
of a human TF-1 cell line and also demonstrated cross-reactivity 
of antihuman CD14, CD163 and CD206 monoclonal antibodies 
against horse PBMC. Furthermore, the myeloid differentiation 
marker ADGRE1 (F4/80) has recently been shown to be expressed 
by equine BMMs.62
Chowdhary et al251 were the first to study the radiation hybrid map 
of the horse genome and found the level of human-horse synteny to 
be greater than the level of mouse-horse synteny. While approximately 
half the number of horse chromosomes showed conserved synteny to 
one human chromosome;235 gene homology is still highly conserved 
between species.252-254 For example, Raudsepp et al found that the 
majority of equine chromosomes show homology to human chromo-
somes; the same group later demonstrated high conservation of gene 
order between horse and human chromosome X. These findings in-
crease the likelihood that discoveries derived from the horse will have 
direct benefits for both equine and human health.
5  | CONCLUSIONS AND FUTURE 
PERSPEC TIVES
In agreement with data derived from other species, the observations 
on the equine MPS summarised in this review refute the concept 
that ‘a macrophage is a macrophage’, highlighting the importance 
of studying cells derived from the specific tissue of interest. Recent 
global analyses on macrophages derived from mouse, human, pig, 
sheep and water buffalo have confirmed that tissue macrophages 
from different anatomical locations differ radically in their gene ex-
pression profiles;61,211,255-257 currently, there are a limited number of 
transcriptomic studies highlighting tissue differences in the horse. 
Graham and co-workers initiated the investigation of the horse tran-
scriptome using human microarrays on equine brain and liver tissues 
and articular chondrocytes.258 Other studies using microarrays22,259 
and RNA-seq260 investigated the equine transcriptome of various 
tissues. Although generally not designed to specifically assess the 
level of tissue macrophage differentiation, extraction and analysis of 
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data derived from these studies clearly demonstrated tissue-specific 
expression profiles which correlate with specialised tissue functions. 
Further expansion of this work is warranted, including the genomic, 
phenotypic and functional characterisation of enzymatically dissoci-
ated macrophage populations derived from different tissues (eg brain 
[microglia], liver [Kupffer cells], spleen (already isolated in our lab) and 
GIT). Furthermore, the relatively recent development of equine tis-
sue banks, such as the Equine Respiratory Tissue bank, University 
of Montreal (http://www.btre.ca/media/ html/en_bioba nk.html) and 
the extensive Thoroughbred-derived biobank described by Burns 
and Roberts (2018), should greatly facilitate the generation of data 
with cross-species translational potential.
Despite extensive research on equine inflammatory diseases, 
specific information on the equine MPS is lacking, largely due to the 
limited availability of appropriate molecular reagents. Consequently, 
many previous studies have relied on the successful use of cross-re-
active human reagents.93,245 With the development of genomic/
transcriptomic resources for the horse234 and emerging data from 
F I G U R E  5   Conservation and divergence of immune genes of the horse—comparison with humans and rodents. Phylogram trees of the 
innate immune response genes CD14 (A), TLR2 (B), TLR3 (C), TLR4 (D), TLR5 (E) and TLR9 (F) of rat, mouse, human and horse. Sequences were 
obtained from www.ensem bl.org (Release 100).271 Analysis was generated by Clustal Omega272 and FigTree v1.4.4 (http://tree.bio.ed.ac.uk/
softw are/figtr ee/). Each gene sequence is presented by species’ official gene name and Ensemble gene ID
Rat CD14 ENSRNOG00000017819
Mouse Tlr2 ENSMUSG00000027995
Rat Tlr4 ENSRNOG00000010522
Mouse Tlr9 ENSMUSG00000045322
Horse TLR9 ENSECAG00000014294
Human TLR9 ENSG00000239732
Rat Tlr9 ENSRNOG00000048161
Horse TLR4 ENSECAG00000010339
Human TLR4 ENSG00000136869
Mouse Tlr4 ENSMUSG00000039005
Rat Tlr2 ENSRNOG00000009822
Horse TLR2 ENSG00000137462
Horse TLR2 ENSECAG00000018028
Mouse CD14 ENSMUSG00000051439
Rat Tlr5 ENSRNOG00000022067
Mouse Tlr5 ENSMUSG00000079164
Human TLR5 ENSG00000187554
Horse TLR5 ENSECAG00000036553
Horse TLR3 ENSECAG00000000197
Human TLR3 ENSG00000164342
Mouse Tlr3 ENSMUSG00000031639
Rat Tlr3 ENSRNOG00000021726
Horse CD14 ENSECAG00000031960
Human CD14 ENSG00000170458
(A) (B)
(C)
(E) (F)
(D)
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numerous other large mammals (human, pig, cattle, sheep and water 
buffalo), it is now increasingly possible to address what is known, 
and what is not known, about the innate immune system of the 
horse in comparison to other species. The equine reference genome, 
EquCab2, from the Thoroughbred mare Twilight was first released in 
2007 and advances in genomic technologies led to a new assembly 
of the reference genome, EquCab3, in 2018 using long-range se-
quencing data to improve contiguity.261 While the equine reference 
genome has led to developments in equine genomics,235 equine ge-
nomic annotation still remains challenging234,262,263 and a high-reso-
lution atlas of equine gene expression would substantially improve 
future efforts in this field.
Justification for the proposal of the horse as an appropriate animal 
model for human macrophage biology would necessitate the global 
analysis of gene expression across multiple tissues in this species. The 
need for defining the tissue-specific gene expression, regulation and 
functional annotation across domestic animal species has already been 
acknowledged by the establishment of the International FAANG proj-
ect.264 The completion of the equine genome annotation would pro-
vide a major tool for future transcriptomic horse studies, the findings 
of which could selectively be applied to humans.
Together, in addition to the important similarities in both patho-
physiology and macrophage/monocyte biology between horses and 
humans, the horse consists a great source of large volumes of dif-
ferent kind of samples that could be used for future studies. The 
volume of equine samples and the associated cell retrieval rates rep-
resent at least 2-3 orders of magnitude greater than those obtained 
from rodent models. Thus, for all these reasons highlighted above, 
we believe that greater consideration should be given to the horse 
as an appropriate candidate model for human disease.
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